These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 24711223)

  • 1. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactinomas: evolution after menopause.
    Mallea-Gil MS; Manavela M; Alfieri A; Ballarino MC; Chervin A; Danilowicz K; Diez S; Fainstein Day P; García-Basavilbaso N; Glerean M; Guitelman M; Katz D; Loto MG; Martinez M; Miragaya K; Moncet D; Rogozinski AS; Servidio M; Stalldecker G; Vitale M; Boero L
    Arch Endocrinol Metab; 2016 Feb; 60(1):42-6. PubMed ID: 26909481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A; Benbassat C; Shimon I
    Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P; Molitch ME
    Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
    Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
    Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
    Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
    J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinoma in postmenopausal women: a systematic review.
    Carneiro MS; de Mira TAA; Yela DA; Benetti-Pinto CL
    Menopause; 2024 Feb; 31(2):160-167. PubMed ID: 38194617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
    Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
    Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.